Clinical trial

Platelet-rich Plasma Injection for Ulnar Neuropathy at Elbow: A Randomized Double-blind Trial

Name

PRP for ulnar neuropathy

Description

Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy after carpal tunnel syndrome (CTS). Although many conservative managements of UNE were found, their effectiveness were often unsatisfied without existed guideline. Recently, the perineural injection of 5% dextrose wate (D5W) is a novel management for CTS but its effect for UNE is not obviously as CTS. Hence, it is very important to find another novel injectate for UNE.

Trial arms

Trial start

2020-08-01

Estimated PCD

2024-03-31

Trial end

2024-03-31

Status

Completed

Treatment

platelet-rich plasma

Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve

Arms:

platelet-rich plasma

5% dextrose

Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve

Arms:

5% dextrose

Size

Primary endpoint

Visual analog scale (VAS)

Change from baseline at 6 month after injection

Eligibility criteria

Inclusion Criteria: 1. Age between 20-80 year-old. 2. Diagnosis as ulnar neuropathy at elbow at least one month Exclusion Criteria: 1. Cancer 2. Coagulopathy 3. Pregnancy 3. Any active infection status 4. Polyneuropathy of upper extremity 5. Brachial plexopathy 6. Thrombocytopenia Previously undergone wrist surgery or steroid injection for ulnar neuropathy

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 30, 'type': 'ACTUAL'}}

Updated at

2024-04-10

1 organization

2 products

1 indication

Organization

Yung-Tsan Wu

Product

Platelet-Rich Plasma

Indication

Ulnar Neuropathy at Elbow

Product

5% Dextrose